Recently, the Beijing Municipal Bureau of Economy and Information Technology announced the list of the first batch of Beijing's "Specialized, Sophisticated, Unique, and New" SMEs for 2023, and Rocgene was successfully selected.

"Specialized, Sophisticated, Unique, and New" enterprises refer to emerging enterprises that focus on specific fields or industries and emphasize innovation and uniqueness. The soul of such enterprises lies in innovation, with scientific and technological strength as their foundation, representing the direction of high-quality development for small and medium-sized enterprises.

Being selected into the list fully affirms Rocgene's development. Since its establishment, Rocgene has been deeply engaged in the field of molecular diagnostics. Committed to developing world-leading life science research and diagnostic products, Rocgene adheres to independent R&D, takes no shortcuts, continuously increases investment in technological innovation, and strives to provide customers with higher-quality products and services.

About Rocgene

Founded in 2016, Rocgene (Beijing) Technology Co., Ltd. is a core-tech-driven biotechnology company established by scientists and industry professionals. Rocgene is dedicated to translating cutting-edge life science technologies into clinically relevant medical research products, developing scientific research and molecular diagnostic products with independent intellectual property rights.

Rocgene has been accredited as a National High-Tech Enterprise and Zhongguancun High-Tech Enterprise, with a 10,000+ square meter clean production facility in Xuzhou High-Tech Zone. To date, the company has obtained 36 patents (18 invention patents, 10 utility model patents, 8 design patents) and 32 software copyrights. With the courage to surpass itself and the ambition to reach new heights, Rocgene aspires to become a forward-looking industry leader.

Rocgene Product Series